Prostate cancer is the second most common cancer and the second leading cause of cancer
death in men. However, prostate cancer can be effectively treated and cured, if it is …

Prostate cancer is the most common malignancy of the urogenital tract. Although
controversial, prostate‐specific antigen (PSA) testing is widely used for screening and follow …

Prostate cancer is the most common cancer among men and the second leading cause of
cancer-related deaths in the United States. CpG island methylation causes gene silencing …

Purpose: Our study was designed to evaluate promoter CpG island hypermethylation in the
diagnosis and prognosis of prostate cancer. Experimental Design: Primary prostate cancers …

Background. Prostate cancer (PCa) is the second most prevalent malignancy among males,
characterized by high mortality rates. Aberrant DNA methylation in promoters of tumor …

Purpose: We investigated the aberrant methylation profile of prostate cancers and correlated
the data with clinical findings. Experimental Design: Gene promoter methylation was …

BACKGROUND A prostate cancer (PCa) biomarker with improved specificity relative to PSA
is a public health priority. Hypermethylated DNA can be detected in body fluids from PCa …

Purpose Patients with prostate cancer who have biochemical recurrence after curative
therapy are at higher risk for distant metastasis and cancer specific death. Assessment of …

Purpose: Promoter hypermethylation is an alternative pathway for gene silencing in
neoplastic cells and a promising cancer detection marker. Although quantitative methylation …

Purpose: The diagnosis of localized prostate cancer is difficult due to a lack of cancer-
specific biomarkers. Many patients require repeat prostate biopsies to diagnose the disease …